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STUDY PROTOCOL

Protocol for a cluster randomised
controlled trial of secondary distribution
of hepatitis C self‑testing within the context
of a house‑to‑house hepatitis C
micro‑elimination programme in Karachi,
Pakistan
Sonjelle Shilton1* , Dania Ali2, Alyia Hasnain2, Adeel Abid2, Jessica Markby1, Muhammad S. Jamil3,
Niklas Luhmann3, Pamela Nabeta1, Stefano Ongarello1, Elena Ivanova Reipold1 and Saeed Hamid2

Abstract
Background: Globally, just 21% of the estimated 58 million people living with hepatitis C virus (HCV) know their
status. Thus, there is considerable need to scale-up HCV testing if the World Health Organization (WHO) 2030 hepatitis
elimination goals are to be achieved. HCV self-testing may assist with this; however, there are currently no data on the
real-world impact of HCV self-testing.
With an estimated 5% of the general population living with HCV, Pakistan has the second highest HCV burden in the
world. This study aims to evaluate the acceptability and impact of home delivery of HCV self-testing for secondary
distribution in the context of a house-to-house HCV micro-elimination programme in Pakistan.
Methods: This is a parallel group, non-blinded, cluster randomised trial comparing secondary distribution of HCV
self-testing with secondary distribution of information pamphlets encouraging individuals to visit a testing facility
for HCV screening. The cluster allocation ratio is 1:1. Clusters will be randomised either to HCV self-testing distributed
via study staff or control clusters where information on HCV will be given and the participant will be requested to
attend their local hospital for HCV screening. In both clusters, only households with a member who has not yet been
screened as part of the larger micro-elimination project will be included. The primary outcome is the number and
proportion of participants who report completion of testing. Secondary outcomes include the number and proportion of participants who a) receive a positive result and are made aware of their status, b) are referred to and complete
HCV RNA confirmatory testing, and c) start treatment. Acceptability, feasibility, attitudes towards HCV testing, and cost
will also be evaluated. The target sample size is 2,000 participants.
Discussion: This study will provide the first ever evidence regarding secondary distribution of HCV self-testing. By
comparing HCV self-testing with facility-based testing, we will assess whether HCV self-testing increases the uptake
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of HCV testing. The findings will inform micro-elimination programmes and determine whether HCV self-testing can
enable individuals to be reached who may otherwise be missed.
Trial Registration: This study and was registered on clinicaltrials.gov (NCT04971538) 21 July 2021.
Keywords: Hepatitis C, Self-testing, Micro-elimination, Pakistan, Testing uptake

Background
Hepatitis C virus (HCV) is a leading cause of liver cancer
globally; however, just 21% of the 58 million individuals
living with HCV have been diagnosed [1]. The diagnosis of HCV currently involves a two-step process: first, a
person receives a facility-based serological test for HCV
antibodies, then, if the result is positive, they receive a
second test to assess for viraemia [2]. The World Health
Organization (WHO) recommends treating all individuals with viraemia with directing-acting antiviral (DAA)
therapy [2].
There is an urgent need to scale-up HCV testing to
achieve the WHO 2030 hepatitis elimination goals [3].
In July 2021, WHO announced the first ever recommendations for HCV self-testing, which state that HCV
self-testing should be offered as an additional approach
to serological testing for HCV antibodies [4]. Self-testing
refers to a process where an individual, either alone or
with someone they trust, performs a test and interprets
the result [4].
HCV self-testing has been shown to be a feasible and
acceptable testing approach that individuals perceive
to be a tool that offers a convenient and private way for
them to learn of their hepatitis C status [5–10]. However,
there are currently no data on the real-world impact of
HCV self-testing, including its effect on uptake of testing
and linkage to care.
With an estimated 5% of its general population living
with HCV, Pakistan has the second highest burden of this
infection in the world [11]. A major scale-up of testing
and treatment is needed if Pakistan is to eliminate HCV
[12]. The current micro-elimination programme, led
by Aga Khan University (AKU), is taking place in three
Union Councils (UC) of Malir District in Karachi, Pakistan: UC-9 (Darsano Chano), UC-10 (Malh) and UC-11
(Murad Memon). This micro-elimination programme
brings HCV screening, diagnostic and treatment services
to people’s doorsteps and aimed to test around 30,000
people, as described previously [13]. However, the current programme has not been able to screen the entirety
of the planned coverage area due to an estimated 39% of
household members being absent when AKU staff made
their field visits. The present study will assess whether
secondary distribution of HCV self-testing can increase
testing uptake among individuals who were unavailable

during the visit by testing campaign staff. In the context of HIV, the secondary distribution of HIV self-tests
during door-to-door testing campaigns substantially
increased testing coverage (by 21%) among absent individuals or those who declined to participate [14]. The
current study will be the first to explore this mode of
delivery of self-testing for HCV.
Study aim and objectives

This study aims to evaluate the acceptability and impact
of the secondary distribution of HCV self-tests in the
context of a house-to-house HCV micro-elimination programme in Malir district, Karachi division, Pakistan. The
primary objective is to assess the impact of HCV selftesting on HCV antibody testing rates. The secondary
objectives are to assess the impact of HCV self-testing
on linkage to and completion of HCV RNA confirmatory testing in HCV antibody-positive individuals and
treatment initiation in HCV RNA-positive individuals
eligible to begin treatment; to assess the acceptability and
feasibility of HCV self-testing; and to assess the cost and
cost-effectiveness of HCV self-testing compared with
facility-based testing.

Methods/design
Design

This is a parallel group, non-blinded, cluster randomised
superiority trial comparing the secondary distribution of
HCV self-tests with the secondary distribution of information pamphlets encouraging individuals to visit a testing facility for HCV screening. A subset of participants
(n = 120) from both the intervention and control groups
will be asked to participate in face-to-face interviews
regarding their perceptions of the testing experience, to
provide insights into the acceptability and feasibility of
HCV self-testing. The study timeline is shown in Table 1.
Study setting

The study will take place in the Malir district of Karachi, Pakistan. Darsano Chano (UC9) is in a rural area
and has a population of approximately 10,000 individuals. Malh (UC10) is peri-urban and has a total population of approximately 50,000 individuals. Both UCs
have small, well-established community clinics, which
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Table 1 Study timeline
Enrolment

Follow-up for
all participants

Follow-up for HCV
antibody-positive
participants

Procedure

Day 1

Months 1–2

Months 1–8

Inclusion and exclusion criteria

X

Informed consent obtained

X

HCV antibody testing (either HCV self-test left with the household or participants in the
control group attend Memon Goth Hospital)

X

X

Collection of test results and survey of perceptions of the testing process

X

Referral of HCV antibody-positive individuals for confirmatory testing and linkage to care

X

X

Linking of data for the RDT (control group) and RNA test and treatment initiation (as
applicable for the intervention and control groups)

X

X

Adverse event (AE)/serious adverse event (SAE) review

X

X

X

Cost data collection and analysis

X

X

X

have formed the hub of the larger ongoing HCV microelimination programme. UC9 and UC10 have approximately 2,000 and 10,000 households, respectively, with
an average of five family members per household.
The study will take place at the homes of eligible
adults visited by study staff. Based on the current
micro-elimination programme, an estimated 7,500
participants remain in both UC9 and UC10 who have
not yet been tested as part of the larger micro-elimination programme. Each UC has been subdivided into
ten blocks/clusters, based on neighbourhood geography, as shown in Figs. 1 and 2; these clusters have not
yet been randomised, but will be matched-pair randomised on a 1:1 basis.
Participants in the control clusters will be directed to
Memon Goth Hospital for facility-based HCV testing;
if a participant tests positive by HCV rapid diagnostic test (RDT), they will immediately have blood drawn
for viraemia testing. As described below, for those in
the self-test group who report a positive self-test, a
member of the AKU team will come to their house to
perform a blood draw for viraemia testing and liver
staging. Treatment for both groups will be provided at
each participant’s doorstep, free of charge, through a
partnership between AKU and The Liver Foundation.
As there is currently no quality-assured HCV selftest available, the professional-use OraQuick® HCV
Rapid Antibody Test, which has been adapted by the
manufacturer for self-testing by being repackaged and
labelled with instructions for use, will be used in this
trial. The OraQuick® HCV Rapid Antibody Test is prequalified by WHO and CE-marked for professional use
(sensitivity 98.1%, specificity 99.6%). The OraQuick®
HCV Self-Test kits provided to participants in the

intervention group will be labelled for Research Use
Only (RUO).
Eligibility criteria

Participants are only eligible to be included in the trial
if they meet all of the following inclusion criteria:
•	 
≥ 18 years of age
• Residing in UC9 or 10
• Not yet reached for testing as part of the larger
micro-elimination programme
• Not known to be HCV antibody-positive
• Not tested for HCV within the past 6 months
• Eligible for inclusion in the larger micro-elimination programme
Participants will be excluded from the trial if they
are at home on the day that AKU study staff visit to
either leave an HCV self-test or the information materials encouraging those who were previously missed to
attend for facility-based HCV testing.
Informed consent

Study staff will explain the nature of the study to the most
senior member of the household present, and who is aged
18 years or more, in a language understandable to her/him,
and answer any questions they have about the study. The
study staff will leave an informed consent form along with
the other study materials. During the telephone call to
report results, the participant will be verbally asked if they
consent to participate in this study. The 120 people who
will be surveyed in the face-to-face interviews will also be
given the opportunity to provide informed consent.
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Fig. 1 Map of UC9. Maps created using Adobe Illustrator 25.4 for Windows. https://www.adobe.com/ro/products/illustrator.html?skwcid=
AL!3085!3!341240180390!e!!g!!adobe%20illustrator&mv=search&sdid=KCJMVLF6&ef_id=CjwKCAiAgbiQBhAHEiwAuQ6Bknh2k612ZgbuSDwb
lwUKE5L1T1KaZATGaxTwAGIkknQrdcWhGZ6JrxoCtNAQAvD_BwE:G:s&s_kwcid=AL!3085!3!341240180390!e!!g!!adobe%20illustrator!1478481991
!58339249918&gclid=CjwKCAiAgbiQBhAHEiwAuQ6Bknh2k612ZgbuSDwblwUKE5L1T1KaZATGaxTwAGIkknQrdcWhGZ6JrxoCtNAQAvD_BwE
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Fig. 2 Map of UC10. Maps created using Adobe Illustrator 25.4 for Windows. https://www.adobe.com/ro/products/illustrator.html?skwcid=
AL!3085!3!341240180390!e!!g!!adobe%20illustrator&mv=search&sdid=KCJMVLF6&ef_id=CjwKCAiAgbiQBhAHEiwAuQ6Bknh2k612ZgbuSDwb
lwUKE5L1T1KaZATGaxTwAGIkknQrdcWhGZ6JrxoCtNAQAvD_BwE:G:s&s_kwcid=AL!3085!3!341240180390!e!!g!!adobe%20illustrator!1478481991
!58339249918&gclid=CjwKCAiAgbiQBhAHEiwAuQ6Bknh2k612ZgbuSDwblwUKE5L1T1KaZATGaxTwAGIkknQrdcWhGZ6JrxoCtNAQAvD_BwE

Trial processes and intervention

The neighbourhoods in UCs 9 and 10 will be grouped
into clusters. These clusters will be matched in terms
of similarity of geography (peri-urban or rural), population size, and age demographics. Each member of a
matched cluster pair will be randomised to the intervention or control groups.
As outlined in Fig. 3, AKU study staff will return to
the households where individuals were missed during
the first round of house-to-house screening carried out
as part of the larger micro-elimination programme. In
the intervention group, the study staff will leave as many
HCV self-tests as there were individuals missed from the
first round of house-to-house screening who are still not
present during the visit, as well as instructions for use,
with the most senior member of the household present.
The study team will also explain the HCV self-testing
process, using a standardised explanatory checklist, to
that same senior member of the household; they will
also leave a mobile phone number for the participant to
call if they need help in conducting the test. Participants
will be provided with various types of support to minimise the occurrence of errors during the self-testing process and any possible confusion in interpretation of the
test results. Printed instructions for use in Urdu will be

delivered with the test kits, which will also contain pictorial guides on how to use the test. Participants will have
access to a live chat facility and a call centre.
In the control group, if the participant(s) are not at
home, the study staff will leave information about HCV
testing and direct them to the nearest clinic that offers
HCV testing services; the participant(s) will not be left
an HCV self-test. Study staff will however leave a mobile
phone number for the participant(s) to call if they need
further information on HCV testing.
In both groups, if no-one is at home or no one aged
18 years or more is present, the study staff will make as
many return visits as necessary to contact a household
member.
A small incentive, comprising a 500 rupee (approximately 3 USD) phone credit voucher, will be provided to
participants in both the intervention and control groups
for any information they return via a phone call, including whether they took the test and, if so, what the result
was. During this return phone call, the study team will
follow up with the participant to inquire whether they
completed the test, record any test results, and conduct
a brief interview.
For all participants who report a positive HCV antibody test, study staff will make an appointment to return
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to their house to enrol them in the larger micro-elimination programme. During this home visit, they will complete a blood draw for HCV viraemia testing and APRI
(aspartate aminotransferase to platelet ratio index) liver
staging, to be performed at Memon Goth Hospital. The
viraemia testing will be performed using an HCV core
antigen assay (ARCHITECT HCV Ag assay, Abbott®
Diagnostics). If a participant’s result is in the grey zone
(≥ 3 to ≤ 10 fmol), a second sample from the same participant will be tested for HCV RNA (Xpert HCV Viral
Load, GeneXpert® IV, Cepheid, France) to determine
viraemia. If the participant is viraemic, further care and
treatment will be provided to their doorstep. All participants who report a negative HCV antibody test will be
encouraged to seek a retest, as per the national guidance.
Approximately 1 month following the start of enrolment, face-to-face interviews will be conducted with a
subset of participants in both the intervention and control groups, to explore their perceptions of the testing
process.
As this study is intended to measure whether there is
an increase in testing following the secondary distribution of HCV self-testing compared with the standard
of care facility-based testing, facility-based testing was
chosen as the comparator. In both groups, if a previously
missed individual is at home when a study staff member
visits, they will enrol the person in the larger micro-elimination programme (and not this study).
Strategies to increase recruitment

As part of the larger micro-elimination programme, AKU
has already established a community oversight board
comprising community leaders from neighbourhoods
UC 9 and 10. This community oversight board has been
informed about this new study component. AKU works
with the community oversight board to sensitise each
neighbourhood to the study, to facilitate information
sharing and encourage interest in participating in the
study.
Outcomes

The primary outcome is to assess whether the proportion
of participants who report completing HCV antibody
testing in the intervention group is greater than that of
the participants in the control group by a margin of 20%.
The secondary outcome measures are as follows.
• The number and estimate of the proportion of HCV
antibody-positive individuals made aware of their
antibody status in the intervention versus the control
group
• The number and estimate of the proportion of HCV
antibody-positive individuals who are referred for
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and complete HCV RNA confirmatory testing in the
intervention versus the control group
• The number and estimate of the proportion of HCV
RNA-positive individuals who begin treatment in the
intervention versus the control group
• The cost per test completed and the cost per person
diagnosed (serology, RNA) in the intervention versus
the control group
• An analysis of the knowledge, attitudes and practice
survey responses will be conducted, using proportions and means
Participant timeline
Sample size

A minimum of 2,000 participants who meet the inclusion
criteria will be enrolled in the study. There will be up to
20 clusters, each comprising up to 150 to 200 households:
5 intervention clusters each in rural and peri-urban areas
and 5 control clusters each in rural and peri-urban areas.
The study is powered to detect at least a 20% betweengroup difference in HCV antibody self-testing, based on
80% statistical power and an alpha level of 0.05.
The survey of participants’ perceptions in relation
to testing will include face-to-face interviews with 60
participants from each of the intervention and control
groups. This is guided by empirical thinking, considering
the feasibility with regards to the time and staff required
to conduct the in-person interviews. The aim of these
interviews is to further expand our understanding of
preferences around HCV self-testing; there is no intention to set specific targets for measurement.
For the primary objective, the null hypothesis is that
there is no significant difference in the proportion of
individuals reporting HCV test results in the intervention versus control groups. The alternative hypothesis
is that home delivery of HCV self-tests will significantly
increase the proportion of individuals reporting HCV
test results.
The study is not powered to detect significant differences in the secondary objectives. However, similar to
the primary objective, the null hypothesis would be no
significant difference between the intervention versus
control groups. The alternative hypothesis would that
home delivery of HCV self-tests will result in significantly higher numbers of HCV-infected individuals being
diagnosed, linked to care and treated, making it a costeffective approach to HCV case finding and elimination.
Assignment of interventions: allocation

Each member (neighbourhood block) of a matched cluster pair will be randomly allocated to the intervention
or control group using a simple, computer-generated
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randomisation list. Each matched pair will be established based on similarities in type of geography (urban/
peri-urban or rural), population size, sex distribution, age
range, income and literacy. Within each UC and type of
cluster (rural versus peri-urban), clusters will be put into
pairs based on average household size (i.e. total estimated
population in the cluster divided by the number of structures in the cluster). For example, the two rural clusters
with the two largest average household sizes will be paired,
followed by the next two rural clusters with the third and
fourth largest average household sizes, and so on. Similar
pairing will be performed for peri-urban clusters. If there
are more than two clusters with the same average household size, then the estimated average age will be used as a
tiebreaker, and pairs will be selected based on the closest
estimated average age in those clusters. Once all clusters
have been put into pairs, each member of a pair will be
randomised to the intervention or control group.
For the face-to-face interviews, a subset of the main
participants will be selected. Based on the study cluster
assignment and testing results, study participants will be
divided into the following eight subgroups:
Intervention group:
• In a rural cluster in the intervention group and completed a test
• In a rural cluster in the intervention group, but did
not complete a test
• In a peri-urban cluster in the intervention group and
completed a test
• In a peri-urban cluster in the intervention group, but
did not complete a test
Control group:
• In a rural cluster in the control group and completed
a test
• In a rural cluster in the control group, but did not
complete a test
• In a peri-urban cluster in the control group and completed a test
• In a peri-urban cluster in the control group, but did
not complete a test
For each subgroup, a randomly ordered list of participants
will be generated via computerised randomisation. Then, for
each subgroup, participants will be contacted by study staff
in descending order on the list until a maximum of 15 individuals in each subgroup have completed the survey.
The trial is not blinded, and the participants and study
staff know which group the participants are assigned to;
therefore, no additional concealment mechanisms will be
used.
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Data collection and management

All participant data relating to the study will be recorded
in source documents and transcribed onto a paper case
report form by the study team. The data will then be
entered into OpenClinica Enterprise Edition, version 4.0,
which is secure and password-protected.
Data for the results return interview (supplementary
material, annex 1) will be collected over the phone. Data
collection for the follow-up interviews among a subset
of participants (supplementary material, annex 2) will
be conducted face-to-face. Both the results return interview and the follow-up interview tools were created specifically for this study. Data relating to further HCV RNA
testing and linkage to care will be extracted from records
at Memon Goth Hospital and AKU treatment partners.
Costing information with regards to costs per test and
costs per person diagnosed with HCV will be collected
and analysed. The data collected will be used to conduct
economic analyses that will include the following:
• The cost of delivering the HCV self-tests, including
associated human resources time
• The cost of conducting an RDT at a local clinic
• The number and type of diagnostic and therapeutic
tests and procedures
• The number of healthcare facility visits before a diagnosis is made, or time to results

Confidentiality

Participants will be assigned a unique identifier, generated by FIND. Any participant records or datasets that
are transferred to FIND will include this identifier only;
no participant names or any other information that would
make the participant identifiable will be transferred.
Statistical methods

The data will be analysed using R version 4.1 or higher.
A summary of statistical analyses that will be completed
by the endpoint is shown in Table 2. The primary analysis will be performed using an intention-to-test analysis. The incentivisation methods described above will be
employed to minimise missing data. The complete analysis plan is described in the study statistical analysis plan,
which was drafted at the time the protocol was developed.
The estimates of the study outcomes are proportions pfo,X,
(fo = favourable outcome, X = element of {intervention, control}). They will be based on the definitions shown in Table 3,
for estimation as well as for between-arm comparison.
The number and estimate of the proportion of participants who report completing HCV antibody testing in
the intervention group will be calculated as:
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Table 2 Statistical analyses to be completed by the endpoint
Endpoint

Statistical analysis method

1.1 The number and estimate of the proportion of participants who report completing HCV antibody testing in the intervention group
1.2 To assess whether the proportion of participants who report completing HCV
antibody testing in the intervention group is greater than that of participants in
the control group, by a margin of 20%

Test of proportions, comparing the proportion of individuals
reporting HCV test results in the intervention versus control
groups and between intervention groups

2.1 The number and estimate of the proportion of HCV antibody-positive individu- Descriptive statistics; statistical tests comparing the number
als made aware of their status in the intervention versus the control group
of individuals in the intervention versus the control group and
between intervention groups
2.2 The number and estimate of the proportion of HCV antibody-positive individuals who are referred to and complete HCV RNA confirmatory testing in the
intervention versus the control group

2.3 The number and estimate of the proportion of HCV RNA-positive individuals
who begin treatment in the intervention versus the control group
2.4 Analysis of survey responses using proportions and means

Descriptive statistics for survey responses (e.g. proportions, means)

2.5 Cost per test completed and cost per person diagnosed (serology, RNA) in the
intervention versus the control group

Ingredients-based cost calculation approach

Table 3 Analysis table for primary and secondary analyses
Outcome
Favourable; test completed

Non-favourable;
test not
completed

Test result and consequence 1

Positive and
referred to further
testing

Test result and consequence 2

Positive and treated Positive and not treated

Study arm

Positive and not
referred to further
testing

negative No result

Intervention a

b

c

d

e

Control

g

h

i

j

Total

f

Total

(a + b + c + e + f + g + h + i)

(e + j)

(a + b + c + d + e)

(f + g + h + i + j)

total

The consequences (referred, treated) will be analysed independently of each other

pfo, I = (a + b + c + d)/(a + b + c + d + e)
pfo, C = (f + g + h + i)/(f + g + h + i + j)
The absolute and relative proportions will be calculated
separately by arm (all arms) and reported with their twosided 95% Wilson score confidence interval.
The difference pfo,I—pfo,C will be assessed using a
one-sided test with a margin of 20%, by applying the following hypothesis:

The alpha level for the analysis will be set at 0.025 (1
one-sided test with an alpha level of 0.025).
The difference and its confidence interval will be estimated using a generalised binary mixed logit model with
“cluster pair” as a random effect and “group” as a fixed
effect (e.g. using the R function “lmer”). The two-sided
95% asymptotic confidence interval will be used to derive
the one-sided lower 97.5% confidence limit, which will be
used for interpretation. In addition, the odds ratio and its
confidence interval will be reported.

H0 : pfo, I − pfo, C ≤ 20%
Oversight and monitoring

HA : pfo, I − pfo, C > 20%
The difference of the proportions in the intervention
and control arms will be reported, together with its
confidence interval (see below) and the p-value related
to the null hypothesis mentioned above.

The support for this study is provided by:
• The principal investigator, who has overall responsibility for the supervision of the study and medical
responsibility for the participants
• An AKU study coordinator, who will ensure that the
field visits to the clusters and participants take place
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according to the schedule and that study procedures
are followed
• AKU study team members, who will conduct the
field visits, record study data, organise payment of
incentives to participants who complete the surveys,
and ensure linkage to the larger micro-elimination
programme as necessary
The study team meets on a weekly basis. There is no
data monitoring committee for this study. This decision
was based on the lack of serious adverse events in previous feasibility and acceptability studies of HCV selftesting completed in Pakistan and six other countries
[4], as well the fact that many large-scale HIV self-testing
studies and pilots have been conducted without such
committees.
The occurrence of any social harms will be monitored
by the community leaders’ steering committee. This
group will follow-up to address any issues that arise and
provide support where necessary. A telephone hotline
will also be made available to participants. Any reports
of social harms will be aggregated into monthly reports.
This study will be guided by a risk-based monitoring
approach. FIND will engage an independent trial monitor, who will conduct a source document review and data
checks on a random selection of 10% of the case report
forms. Any protocol amendments will be notified to the
AKU Ethics Review Committee.
Dissemination plans

The results of this research will be widely disseminated,
targeting community groups, academia, implementers
and policymakers, using a variety of methods. A national
dissemination event will be held, which will aim to bring
together community and health professionals. The results
of the study will be written up and submitted for presentation at international conferences and publication in
peer-reviewed journals.

Discussion
Globally, almost four out of five individuals with chronic
HCV infection were estimated to be undiagnosed in 2019
[1]. The current facility- and community-based testing approaches alone are not reaching a major proportion of those who remain undiagnosed for HCV. New
approaches are needed to address this gap. WHO now
recommends HCV self-testing as an additional approach
to HCV testing services [3]. We are conducting the first
study of real-world implementation of HCV self-testing, in a pragmatic, cluster randomised trial in a setting
where there is a high burden of HCV, to assess the uptake
of testing and related outcomes.
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Strengths

This study will provide the first ever evidence use of secondary distribution of HCV self-testing. By using a randomised approach to compare HCV self-testing with
facility-based testing, we will gain insights into whether
the availability of HCV self-testing increases the uptake
of HCV testing. In the context of the COVID-19 pandemic, wherein individuals’ movements around Pakistan
may become very restricted, the provision of home-based
HCV self-testing may help to mitigate some of the negative
impacts the pandemic has had on the hepatitis programme.
Limitations

This study has some important limitations that will
be considered and described in the study report. The
uptake of testing in the control arm may be affected by
the geographical location of the participant and the distance to Memon Goth Hospital, as well as by the ongoing COVID-19 pandemic, which may affect participants’
willingness to visit a healthcare facility. The interview
questionnaires have a multiple-choice design, which may
not capture some important context-specific aspects.
Cluster randomised trials have the possibility of crosscontamination bias; however, in this study the risk of
cross-contamination bias is limited, because the control
group will not have access to HCV self-tests as they are
not currently on the market in Pakistan. Given that the
time between enrolment and result return is expected to
take up to a maximum of 1 month, incentives are offered
for the return of results, and “did not complete the test”
is an option for the return of the results; therefore we are
not anticipating a large attrition bias. Detection bias will
be minimised by clearly defining the study procedures
used to measure the outcomes and by using the same
procedures and data collection tools in both the intervention and control groups, for example the result reporting
procedure is the same across both the intervention and
control groups, with the same data collection tool, result
reporting procedure, and result reporting timeframe.
The WHO HCV self-testing guidelines recommend that HCV self-testing delivery models, support
tools and referral pathways are designed and adapted
according to the local context and community preferences. This study will provide an opportunity to pilot
implementation approaches and explore their feasibility in the context of micro-elimination efforts. These
approaches can be refined and optimised for broader
use in national testing plans, based on the lessons
learned. Given the significant burden of HCV in Pakistan and elsewhere, this study will inform efforts to
scale-up approaches to diagnose individuals with HCV
who would otherwise not access testing and link them
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to effective treatment. Further studies can be conducted to assess other implementation models in different settings.

Trial status
Protocol V 1.0, 6 July 2021. Enrolment began in
November 2021 and is expected to be completed in Q1
of 2022.
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council; WHO: World Health Organization.
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